CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Both as oral monotherapy and in combination with cetuximab, adagrasib exhibited antitumor activity in patients who had received prior treatment and had metastatic colorectal cancer with mutant KRAS G12C. In the group receiving combination therapy, the median response time was greater than 6 months. Reversible negative outcomes were frequent in both groups.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
